Clinical ResearchHeart Rhythm DisorderSynergistic Effect of the Combination of Ranolazine and Dronedarone to Suppress Atrial Fibrillation
Heart Rhythm Disorder
Under an Elsevier user license
open archive
Key Words
antiarrhythmic drugs
arrhythmias
electrophysiology
pharmacology
sodium-channel blockers
Abbreviations and Acronyms
ACh
acetylcholine
AF
atrial fibrillation
AP
action potential
APD
action potential duration
CL
cycle length
DAD
delayed afterdepolarization
DTE
diastolic threshold of excitation
ERP
effective refractory period
INa
sodium channel current
LV
left ventricular
PRR
post-repolarization refractoriness
PV
pulmonary vein
RA
right atrial
Vmax
maximal rate of rise of the action potential upstroke
Cited by (0)
This study was supported by grants from Gilead Sciences, the National Institutes of Health (grant HL-47678 to Dr. Antzelevitch), and the New York State and Florida Grand Lodges of Free and Accepted Masons. Dr. Antzelevitch received research support from Gilead Sciences, AstraZeneca, Merck, and Cardiome; and consulting support from Gilead Sciences and AstraZeneca. Dr. Belardinelli is an employee of Gilead Sciences. All other authors have reported that they have no relationships to disclose.
Copyright © 2010 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.